0001193125-19-206299.txt : 20190730 0001193125-19-206299.hdr.sgml : 20190730 20190730090402 ACCESSION NUMBER: 0001193125-19-206299 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20190730 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190730 DATE AS OF CHANGE: 20190730 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 19983383 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 8-K 1 d757920d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 30, 2019

 

 

HCA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-11239   27-3865930

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

One Park Plaza, Nashville,

Tennessee

  37203
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (615) 344-9551

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $.01 par value per share    HCA    New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

 

 

 


Item 2.02. Results of Operations and Financial Condition.

On July 30, 2019, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2019, the text of which is set forth as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

On July 30, 2019, the Company issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2019, the text of which is set forth as Exhibit 99.1.

Item 8.01. Other Events.

On July 30, 2019, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.40 per share of the Company’s common stock. The dividend will be paid on September 30, 2019 to stockholders of record at the close of business on September 3, 2019.

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits:

 

Exhibit 99.1    Press Release, dated July 30, 2019.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HCA HEALTHCARE, INC.
 

/s/ William B. Rutherford

 

William B. Rutherford

Executive Vice President and Chief Financial Officer

Date: July 30, 2019

EX-99.1 2 d757920dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO             LOGO

 

   FOR IMMEDIATE RELEASE
INVESTOR CONTACT:    MEDIA CONTACT:
Mark Kimbrough    Ed Fishbough
615-344-2688    615-344-2810

HCA Reports Second Quarter 2019 Results

Updates 2019 Guidance

Nashville, Tenn., July 30, 2019 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2019.

Key second quarter metrics (all percentage changes compare 2Q 2019 to 2Q 2018 unless otherwise noted):

 

   

Revenues totaled $12.602 billion

 

   

Net income attributable to HCA Healthcare, Inc. totaled $783 million, or $2.25 per diluted share

 

   

Adjusted EBITDA totaled $2.293 billion

 

   

Cash flows from operating activities totaled $1.997 billion

 

   

Same facility equivalent admissions and same facility admissions increased 2.6 percent and 2.1 percent, respectively

Revenues in the second quarter of 2019 increased to $12.602 billion, compared to $11.529 billion in the second quarter of 2018. Net income attributable to HCA Healthcare, Inc. totaled $783 million, or $2.25 per diluted share, compared to $820 million, or $2.31 per diluted share, in the second quarter of 2018. Results for the second quarter of 2019 include gains on sales of facilities of $18 million, or $0.04 per diluted share. Second quarter of 2018 results included gains on sales of facilities of $9 million, or $0.02 per diluted share.

For the second quarter of 2019, Adjusted EBITDA totaled $2.293 billion, compared to $2.227 billion in the second quarter of 2018. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions increased 2.1 percent and same facility equivalent admissions increased 2.6 percent in the second quarter of 2019 compared to the prior year period. Same facility emergency room visits increased 3.0 percent in the second quarter of 2019, compared to the prior year period. Same facility inpatient surgeries declined 0.1 percent, while same facility outpatient surgeries increased 0.6 percent in the second quarter of 2019 compared to the same period of 2018. Same facility revenue per equivalent admission increased 1.7 percent in the second quarter of 2019 compared to the second quarter of 2018.

 

1


Salaries and benefits, supplies and other operating expenses totaled $10.317 billion, or 81.9 percent of revenues, in the second quarter of 2019, compared to $9.309 billion, or 80.8 percent of revenues, in the second quarter of 2018.

Six Months Ended June 30, 2019

Revenues for the six months ended June 30, 2019 totaled $25.119 billion compared to $22.952 billion in the same period of 2018. Net income attributable to HCA Healthcare, Inc. was $1.822 billion, or $5.22 per diluted share, compared to $1.964 billion, or $5.50 per diluted share, for the first six months of 2018. Results for the six months ended June 30, 2019 include gains on sales of facilities of $17 million, or $0.04 per diluted share. Results for the six months ended June 30, 2018 included gains on sales of facilities of $414 million, or $0.88 per diluted share.

Balance Sheet and Cash Flows from Operations

As of June 30, 2019, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $2.430 billion, total debt of $36.193 billion, and total assets of $45.449 billion. During the second quarter of 2019, capital expenditures totaled $964 million, excluding acquisitions. Cash flows provided by operating activities in the second quarter totaled $1.997 billion, compared to $1.582 billion in the second quarter of 2018.

During June 2019, we issued $5.000 billion aggregate principal amount of senior secured notes comprised of $2.000 billion aggregate principal amount of 4 1/8% senior secured notes due 2029, $1.000 billion aggregate principal amount of 5 1/8% senior secured notes due 2039 and $2.000 billion aggregate principal amount of 5 1/4% senior secured notes due 2049. During June 2019, we used the proceeds to temporarily reduce balances under our asset-based revolving credit facility.

During July 2019, we redeemed all $600 million outstanding aggregate principal amount of 4.25% senior secured notes due 2019, all $3.000 billion outstanding aggregate principal amount of 6.50% senior secured notes due 2020 and all $1.350 billion outstanding aggregate principal amount of 5.875% senior secured notes due 2022. Pretax losses on retirement of debt totaling $211 million for these redemptions will be recognized during the quarter ending September 30, 2019.

During the second quarter of 2019, the Company repurchased 1.928 million shares of its common stock at a cost of $242 million. For the six months ended June 30, 2019, the Company has repurchased 4.034 million shares at a cost of $520 million. The Company had $1.753 billion remaining under its existing repurchase authorization as of June 30, 2019.

Dividend

HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.40 per share on the Company’s common stock. The dividend will be paid on September 30, 2019 to stockholders of record at the close of business on September 3, 2019.

The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition and results of operations

 

2


and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.

2019 Guidance

The 2019 guidance ranges for the year are revised from our first quarter release and are as follows:

 

     2019 Revised Guidance Range

Revenues

  

$50.5 to $51.5 billion

Adjusted EBITDA

  

$9.60 to $9.85 billion

EPS (diluted)

  

$10.25 to $10.65 per diluted share

Capital Expenditures        

  

Approximately $3.7 billion

The Company’s 2019 guidance contains a number of assumptions, including:

 

   

2019 guidance includes estimated financial impact of the Company’s Mission Health acquisition, which closed February 1, 2019.

 

   

2019 guidance excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claim costs and impairments of long-lived assets.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”

Earnings Conference Call

HCA will host a conference call for investors at 9:00 a.m. Central Daylight Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed at: https://event.webcasts.com/starthere.jsp?ei=1234726&tp_key=fae8205a1b or through the Company’s Investor Relations web page at www.hcahealthcare.com.

About the Company

As of June 30, 2019, HCA operated 184 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 21 states and the United Kingdom.

 

3


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending December 31, 2019, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, (2) the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Health Reform Law”), including the effects of court challenges to, any repeal of, or changes to, the Health Reform Law or additional changes to its implementation, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state or local laws or regulations affecting the health care industry, (3) the effects related to the continued implementation of the sequestration spending reductions required under the Budget Control Act of 2011, and related legislation extending these reductions, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (4) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (5) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (6) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (7) the highly competitive nature of the health care business, (8) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (9) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (10) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (11) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (12) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (13) changes in accounting practices, (14) changes in general economic conditions nationally and regionally in our markets, (15) the emergence of and effects related to infectious diseases, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of potential cybersecurity incidents or security breaches, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology, (23) the impact of natural disasters,

 

4


such as hurricanes and floods, or similar events beyond our control, (24) the effects of the 2017 Tax Cuts and Jobs Act, including potential legislation or interpretive guidance that may be issued by federal and state taxing authorities or other standard-setting bodies, and (25) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2018 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

 

5


HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

Second Quarter

(Dollars in millions, except per share amounts)

 

     2019     2018  
     Amount     Ratio     Amount     Ratio  

Revenues

   $ 12,602       100.0   $ 11,529       100.0

Salaries and benefits

     5,837       46.3       5,274       45.8  

Supplies

     2,118       16.8       1,917       16.6  

Other operating expenses

     2,362       18.8       2,118       18.4  

Equity in earnings of affiliates

     (8     (0.1     (7     (0.1

Depreciation and amortization

     636       5.0       562       4.9  

Interest expense

     477       3.8       436       3.8  

Gains on sales of facilities

     (18     (0.1     (9     (0.1
  

 

 

   

 

 

   

 

 

   

 

 

 
     11,404       90.5       10,291       89.3  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     1,198       9.5       1,238       10.7  

Provision for income taxes

     271       2.1       272       2.3  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     927       7.4       966       8.4  

Net income attributable to noncontrolling interests

     144       1.2       146       1.3  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to HCA Healthcare, Inc.

   $ 783       6.2     $ 820       7.1  
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted earnings per share

   $ 2.25       $ 2.31    

Shares used in computing diluted earnings per share (millions)

     348.373         355.039    

Comprehensive income attributable to HCA Healthcare, Inc.

   $ 726       $ 756    
  

 

 

     

 

 

   

 

6


HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

For the Six Months Ended June 30, 2019 and 2018

(Dollars in millions, except per share amounts)

 

     2019     2018  
     Amount     Ratio     Amount     Ratio  

Revenues

   $ 25,119       100.0   $ 22,952       100.0

Salaries and benefits

     11,484       45.7       10,563       46.0  

Supplies

     4,159       16.6       3,832       16.7  

Other operating expenses

     4,661       18.6       4,228       18.5  

Equity in earnings of affiliates

     (19     (0.1     (16     (0.1

Depreciation and amortization

     1,255       5.0       1,115       4.8  

Interest expense

     938       3.7       867       3.8  

Gains on sales of facilities

     (17     (0.1     (414     (1.8
  

 

 

   

 

 

   

 

 

   

 

 

 
     22,461       89.4       20,175       87.9  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     2,658       10.6       2,777       12.1  

Provision for income taxes

     550       2.2       529       2.3  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     2,108       8.4       2,248       9.8  

Net income attributable to noncontrolling interests

     286       1.1       284       1.2  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to HCA Healthcare, Inc.

   $ 1,822       7.3     $ 1,964       8.6  
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted earnings per share

   $ 5.22       $ 5.50    

Shares used in computing diluted earnings per share (millions)

     349.334         357.388    

Comprehensive income attributable to HCA Healthcare, Inc.

   $ 1,772       $ 1,981    
  

 

 

     

 

 

   

 

7


HCA Healthcare, Inc.

Condensed Consolidated Balance Sheets

(Dollars in millions)

 

     June 30,
2019
    March 31,
2019
    December 31,
2018
 

ASSETS

      

Current assets:

      

Cash and cash equivalents

   $ 2,430     $ 531     $ 502  

Accounts receivable

     7,219       7,420       6,789  

Inventories

     1,826       1,778       1,732  

Other

     1,394       1,379       1,190  
  

 

 

   

 

 

   

 

 

 

Total current assets

     12,869       11,108       10,213  

Property and equipment, at cost

     45,369       44,583       42,965  

Accumulated depreciation

     (23,902     (23,455     (23,208
  

 

 

   

 

 

   

 

 

 
     21,467       21,128       19,757  

Investments of insurance subsidiaries

     342       338       362  

Investments in and advances to affiliates

     247       246       232  

Goodwill and other intangible assets

     8,140       8,159       7,953  

Right-of-use operating lease assets

     1,787       1,812        

Other

     597       588       690  
  

 

 

   

 

 

   

 

 

 
   $ 45,449     $ 43,379     $ 39,207  
  

 

 

   

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

      

Current liabilities:

      

Accounts payable

   $ 2,609     $ 2,693     $ 2,577  

Accrued salaries

     1,497       1,424       1,580  

Other accrued expenses

     2,782       2,618       2,624  

Long-term debt due within one year

     2,073       3,796       788  
  

 

 

   

 

 

   

 

 

 

Total current liabilities

     8,961       10,531       7,569  

Long-term debt, less debt issuance costs and discounts of $252, $170 and $157

     34,120       31,019       32,033  

Professional liability risks

     1,354       1,313       1,275  

Right-of-use operating lease obligations

     1,460       1,494        

Income taxes and other liabilities

     1,324       1,277       1,248  

EQUITY (DEFICIT)

      

Stockholders’ deficit attributable to HCA Healthcare, Inc.

     (3,902     (4,354     (4,950

Noncontrolling interests

     2,132       2,099       2,032  
  

 

 

   

 

 

   

 

 

 

Total deficit

     (1,770     (2,255     (2,918
  

 

 

   

 

 

   

 

 

 
   $ 45,449     $ 43,379     $ 39,207  
  

 

 

   

 

 

   

 

 

 

 

8


HCA Healthcare, Inc.

Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2019 and 2018

(Dollars in millions)

 

     2019     2018  

Cash flows from operating activities:

    

Net income

   $ 2,108     $ 2,248  

Adjustments to reconcile net income to net cash provided by operating activities:

    

Increase (decrease) in cash from operating assets and liabilities:

    

Accounts receivable

     (174     (233

Inventories and other assets

     (231     (200

Accounts payable and accrued expenses

     (238     31  

Depreciation and amortization

     1,255       1,115  

Income taxes

     27       118  

Gains on sales of facilities

     (17     (414

Amortization of debt issuance costs and discounts

     16       15  

Share-based compensation

     158       134  

Other

     67       51  
  

 

 

   

 

 

 

Net cash provided by operating activities

     2,971       2,865  
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchase of property and equipment

     (1,745     (1,574

Acquisition of hospitals and health care entities

     (1,504     (538

Disposition of hospitals and health care entities

     41       799  

Change in investments

     59       23  

Other

     36       (25
  

 

 

   

 

 

 

Net cash used in investing activities

     (3,113     (1,315
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Issuance of long-term debt

     6,451        

Net change in revolving credit facilities

     (3,040     210  

Repayment of long-term debt

     (98     (101

Distributions to noncontrolling interests

     (247     (185

Payment of debt issuance costs

     (63     (2

Payment of cash dividends

     (278     (245

Repurchase of common stock

     (520     (893

Other

     (135     (192
  

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     2,070       (1,408
  

 

 

   

 

 

 

Effect of exchange rate changes on cash and cash equivalents

           (6
  

 

 

   

 

 

 

Change in cash and cash equivalents

     1,928       136  

Cash and cash equivalents at beginning of period

     502       732  
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 2,430     $ 868  
  

 

 

   

 

 

 

Interest payments

   $ 910     $ 873  

Income tax payments, net

   $ 523     $ 411  

 

9


HCA Healthcare, Inc.

Operating Statistics

 

     Second Quarter     For the Six Months
Ended June 30,
 
     2019     2018     2019     2018  

Operations:

        

Number of Hospitals

     184       178       184       178  

Number of Freestanding Outpatient Surgery Centers

     125       122       125       122  

Licensed Beds at End of Period

     48,483       46,723       48,483       46,723  

Weighted Average Licensed Beds

     48,429       46,667       48,234       46,676  

Reported:

        

Admissions

     518,253       494,610       1,041,449       1,002,483  

% Change

     4.8       3.9  

Equivalent Admissions

     903,419       851,047       1,793,375       1,700,211  

% Change

     6.2       5.5  

Revenue per Equivalent Admission

   $ 13,949     $ 13,547     $ 14,007     $ 13,499  

% Change

     3.0       3.8  

Inpatient Revenue per Admission

   $ 14,295     $ 13,807     $ 14,353     $ 13,756  

% Change

     3.5       4.3  

Patient Days

     2,530,548       2,370,306       5,137,445       4,902,025  

% Change

     6.8       4.8  

Equivalent Patient Days

     4,412,348       4,080,800       8,846,680       8,313,834  

% Change

     8.1       6.4  

Inpatient Surgery Cases

     140,473       137,403     277,836       272,439

% Change

     2.2       2.0  

Outpatient Surgery Cases

     253,441       246,013     494,287       478,496

% Change

     3.0       3.3  

Emergency Room Visits

     2,253,337       2,148,338       4,540,777       4,450,450  

% Change

     4.9       2.0  

Outpatient Revenues as a

        

Percentage of Patient Revenues

     39.1     38.6     38.5     37.9

Average Length of Stay (days)

     4.883       4.792       4.933       4.890  

Occupancy

     57.4     55.8     58.8     58.0

Same Facility:

        

Admissions

     491,394       481,361       990,418       974,795  

% Change

     2.1       1.6  

Equivalent Admissions

     849,129       827,460       1,690,644       1,652,278  

% Change

     2.6       2.3  

Revenue per Equivalent Admission

   $ 13,803     $ 13,574     $ 13,932     $ 13,523  

% Change

     1.7       3.0  

Inpatient Revenue per Admission

   $ 14,321     $ 13,853     $ 14,399     $ 13,773  

% Change

     3.4       4.5  

Inpatient Surgery Cases

     132,815       132,963       263,088       263,283  

% Change

     -0.1       -0.1  

Outpatient Surgery Cases

     240,389       239,036       469,607       465,061  

% Change

     0.6       1.0  

Emergency Room Visits

     2,151,662       2,088,311       4,339,334       4,323,807  

% Change

     3.0       0.4  

 

*

Reclassifications between inpatient surgery cases and outpatient surgery cases for 2018 have been made to conform to the 2019 presentation.

 

10


HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

Operating Results Summary

(Dollars in millions, except per share amounts)

 

     Second Quarter     For the Six Months
Ended June 30,
 
     2019     2018     2019     2018  

Revenues

   $ 12,602     $ 11,529     $ 25,119     $ 22,952  

Net income attributable to HCA Healthcare, Inc.

   $ 783     $ 820     $ 1,822     $ 1,964  

Gains on sales of facilities (net of tax)

     (14     (8     (13     (313
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities (a)

     769       812       1,809       1,651  

Depreciation and amortization

     636       562       1,255       1,115  

Interest expense

     477       436       938       867  

Provision for income taxes

     267       271       546       428  

Net income attributable to noncontrolling interests

     144       146       286       284  
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA (a)

   $ 2,293     $ 2,227     $ 4,834     $ 4,345  
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA margin (a)

     18.2     19.3     19.2     18.9

Diluted earnings per share:

        

Net income attributable to HCA Healthcare, Inc.

   $ 2.25     $ 2.31     $ 5.22     $ 5.50  

Gains on sales of facilities

     (0.04     (0.02     (0.04     (0.88
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities (a)

   $ 2.21     $ 2.29     $ 5.18     $ 4.62  
  

 

 

   

 

 

   

 

 

   

 

 

 

Shares used in computing diluted earnings per share (millions)

     348.373       355.039       349.334       357.388  

 

(a)

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

 

    

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that gains on sales of facilities will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

 

    

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

11


HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

2019 Operating Results Forecast

(Dollars in millions, except per share amounts)

 

 

     For the Year Ending  
     December 31, 2019  
     Low      High  

Revenues

   $ 50,500      $ 51,500  

Net income attributable to HCA Healthcare, Inc. (a)

   $ 3,580      $ 3,720  

Depreciation and amortization

     2,535        2,575  

Interest expense

     1,825        1,850  

Provision for income taxes

     1,070        1,115  

Net income attributable to noncontrolling interests

     590        590  
  

 

 

    

 

 

 

Adjusted EBITDA (a) (b)

   $ 9,600      $ 9,850  
  

 

 

    

 

 

 

Diluted earnings per share:

     

Net income attributable to HCA Healthcare, Inc.

   $ 10.25      $ 10.65  

Shares used in computing diluted earnings per share (millions)

     349.200        349.200  

The Company’s forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.

 

(a)

The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.

 

(b)

Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles (“GAAP”). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.

 

    

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.    

 

    

Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.    

 

12

GRAPHIC 3 g757920page1.jpg GRAPHIC begin 644 g757920page1.jpg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end GRAPHIC 4 g757920page1a.jpg GRAPHIC begin 644 g757920page1a.jpg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end